physioneal 35 glucose 3.86% w/v / 38.6 mg/ml clear-flex,solution for peritoneal dialysis
baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 3.86 percent weight/volume - hypertonic solutions
physioneal 40 glucose 1.36% w/v / 13.6 mg/ml clear-flex,solution for peritoneal dialysis
baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 1.36 percent weight/volume - hypertonic solutions
physioneal 40 glucose 2.27% w/v / 22.7 mg/ml clear-flex,solution for peritoneal dialysis
baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 2.27 percent weight/volume - hypertonic solutions
physioneal 40 glucose 3.86% w/v / 38.6 mg/ml clear-flex,solution for peritoneal dialysis
baxter holding b.v. - glucose monohydrate; sodium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium (s)-lactate solution; sodium bicarbonate - solution for peritoneal dialysis - 3.86 percent weight/volume - hypertonic solutions
potassium chloride 0.15%w/v sodium chloride 0.18%w/v glucose 4%w/v solution for infusion
carelide - glucose monohydrate; sodium chloride; potassium chloride - solution for infusion - 0.15 0.18 4 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates
glucose 10% w/v
fresenius kabi new zealand limited - glucose monohydrate 110 g/l equivalent to glucose 100 g/l; - solution for infusion - 100 g/l - active: glucose monohydrate 110 g/l equivalent to glucose 100 g/l excipient: hydrochloric acid sodium hydroxide water for injection - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used. b) gastrointestinal absorption of protein is impaired. c) metabolic requirements for protein are substantially increased, as with extensive burns.
baxter 5% glucose intravenous infusion glucose 1000ml bag
baxter healthcare pty ltd - glucose, quantity: 45 g (equivalent: glucose monohydrate, qty 50 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.
baxter 5% glucose intravenous infusion glucose 500ml bag
baxter healthcare pty ltd - glucose, quantity: 22.5 g (equivalent: glucose monohydrate, qty 25 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.
baxter 5% glucose intravenous infusion glucose 250ml bag
baxter healthcare pty ltd - glucose, quantity: 11.25 g (equivalent: glucose monohydrate, qty 12.5 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.
glucose 5%
b braun medical (pty) ltd - glucose monohydrate - infusion - each 1000ml solution contains glucose monohydrate equiv. to glucose (anhydrous) 50,0 g